REGENXBIO Inc.
RGNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Valued at $441.0M, RGNX is a small-cap name in its sector. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Market Cap
$441.0M
Beta
1.13
P/E (TTM)
—
P/E (Fwd)
-2.25
EPS (TTM)
$-3.78
EPS (Fwd)
$-2.97
ROE
-137.6%
ROA
-21.2%
Cash
$105.5M
Total Debt
$250.5M
Free CF
-$184.3M
52W Change
-50.9%
Annual Financials
Cash vs Debt
Where RGNX stands vs its 150-day and 200-day moving averages
As of the October 6, 2026 close, RGNX finished 14.91% below its 150-day moving average ($9.12) and 21.22% below its 200-day moving average ($9.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RGNX overbought or oversold?
At the October 6, 2026 close, RGNX's RSI(14) was 46.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, RGNX has $105.5M in cash with $250.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$184.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -137.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $112.7M to $170.4M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence REGENXBIO Inc.'s trajectory.